Skip to main content

Free Content Pricing of drugs and donations: options for sustainable equity pricing

Download Article:

The full text article is temporarily unavailable.

We apologise for the inconvenience. Please try again later.

Abstract:

Effective medicines exist to treat or alleviate many diseases which predominate in the developing world and cause high mortality and morbidity rates. Price should not be an obstacle preventing access to these medicines. Increasingly, drug donations have been established by drug companies, but these are often limited in time, place or use. Measures exist which are more sustainable and will have a greater positive impact on people’s health. Principally, these are encouraging generic competition; adopting into national legislation and implementing TRIPS safeguards to gain access to cheaper sources of drugs; differential pricing; creating high volume or high demand through global and regional procurement; and supporting the production of quality generic drugs by developing countries through voluntary licenses if needed, and facilitating technology transfer.

Keywords: antiretrovirals; azithromycin; compulsory licensing; cryptococcal meningitis; donation; fluconazole; generic drug; leishmaniasis; parallel import; pricing; trachoma

Document Type: Research Article

Publication date: November 1, 2001

bsc/tmih/2001/00000006/00000011/art00801
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more